{"title":"Electrocardiographic and biochemical predictors of left ventricular remodeling early after ST-segment elevation myocardial infarction.","authors":"Mert Doğan, Uğur Canpolat, Kudret Aytemir","doi":"10.1080/14796678.2024.2424128","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> We aimed to assess low to mid-range left ventricular ejection fraction (LVEF) predictors at one-month follow-up in STEMI patients using baseline electrocardiography (ECG) and standard laboratory tests.<b>Methods:</b> In this retrospective cross-sectional study, 130 STEMI patients (79% male, mean age: 57.2 ± 11.9 years) were enrolled. Multivariate linear regression analysis determined the relationship of baseline 12-lead ECG and clinical/laboratory parameters with LVEF at the 1st-month follow-up visit.<b>Results:</b> The mean LVEF of the patients at the 1st-month follow-up visit was 51.8 ± 8.7%. There was a significant negative correlation between age (r = -0.206)*, peak CK-MB level (-0.0411)**, QTc interval (r = -0.209)*, STE amount (mV) (r = -0.286)**, V<sub>5-6</sub> RWPT (r = -0.238)** and aVR RWPT (r = -0.466)** with LVEF (*<i>p</i> < 0.05; **<i>p</i> < 0.01). The aVR R wave peak time (RWPT) (OR: 0.88, <i>p</i> < 0.01) and peak CK-MB level (OR: 0.91, <i>p</i> < 0.01) were the two most important predictors of low-to-mid-range LVEF (<%50) during mean 38 ± 5 days follow-up after STEMI.<b>Conclusion:</b> Our study results suggested that the baseline aVR RWPT and peak CK-MB level were associated with low-to-mid-range LVEF at the 1st-month follow-up after STEMI. These parameters may be used in the risk stratification of STEMI patients to develop LV remodeling during follow-up.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-8"},"PeriodicalIF":1.6000,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/14796678.2024.2424128","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: We aimed to assess low to mid-range left ventricular ejection fraction (LVEF) predictors at one-month follow-up in STEMI patients using baseline electrocardiography (ECG) and standard laboratory tests.Methods: In this retrospective cross-sectional study, 130 STEMI patients (79% male, mean age: 57.2 ± 11.9 years) were enrolled. Multivariate linear regression analysis determined the relationship of baseline 12-lead ECG and clinical/laboratory parameters with LVEF at the 1st-month follow-up visit.Results: The mean LVEF of the patients at the 1st-month follow-up visit was 51.8 ± 8.7%. There was a significant negative correlation between age (r = -0.206)*, peak CK-MB level (-0.0411)**, QTc interval (r = -0.209)*, STE amount (mV) (r = -0.286)**, V5-6 RWPT (r = -0.238)** and aVR RWPT (r = -0.466)** with LVEF (*p < 0.05; **p < 0.01). The aVR R wave peak time (RWPT) (OR: 0.88, p < 0.01) and peak CK-MB level (OR: 0.91, p < 0.01) were the two most important predictors of low-to-mid-range LVEF (<%50) during mean 38 ± 5 days follow-up after STEMI.Conclusion: Our study results suggested that the baseline aVR RWPT and peak CK-MB level were associated with low-to-mid-range LVEF at the 1st-month follow-up after STEMI. These parameters may be used in the risk stratification of STEMI patients to develop LV remodeling during follow-up.
期刊介绍:
Research advances have contributed to improved outcomes across all specialties, but the rate of advancement in cardiology has been exceptional. Concurrently, the population of patients with cardiac conditions continues to grow and greater public awareness has increased patients" expectations of new drugs and devices. Future Cardiology (ISSN 1479-6678) reflects this new era of cardiology and highlights the new molecular approach to advancing cardiovascular therapy. Coverage will also reflect the major technological advances in bioengineering in cardiology in terms of advanced and robust devices, miniaturization, imaging, system modeling and information management issues.